Cordyceps mushrooms have been used in traditional East Asian medicine for centuries, particularly in the context of respiratory and lung health. Modern research is beginning to examine the biological mechanisms behind these traditional uses, with several clinical and preclinical studies suggesting that Cordyceps-derived compounds may support respiratory function through anti-inflammatory, bronchodilatory, and microbiome-mediated pathways.
What Are Cordyceps Mushrooms?
The term “Cordyceps” broadly encompasses several species, most notably Cordyceps sinensis (now reclassified as Ophiocordyceps sinensis) and Cordyceps militaris. Wild C. sinensis grows at high altitudes in the Tibetan Plateau and has historically been used to address fatigue, weakness, and respiratory complaints. C. militaris is more widely cultivated and has become the dominant commercial species used in modern supplements.
The primary bioactive compounds include cordycepin (3′-deoxyadenosine), adenosine, polysaccharides, and various cordycepic acids. Cordycepin in particular has attracted significant research interest for its potential immune-modulatory and anti-inflammatory effects.
Cordyceps and Chronic Obstructive Pulmonary Disease (COPD)
COPD is a progressive respiratory condition characterized by airflow limitation and chronic inflammation of the airways. Several clinical trials have investigated Cordyceps-based preparations as adjunctive therapies alongside standard COPD management.
A meta-analysis of 27 randomized controlled trials evaluating Bailing capsules, a standardized preparation derived from cultured Cordyceps sinensis, found significant improvements in key lung function markers including forced expiratory volume in one second (FEV1), the FEV1/FVC ratio, and six-minute walk test distances compared with standard care alone. Researchers also observed a reduction in acute exacerbation rates.[1]
A separate multicenter randomized controlled trial comparing two Cordyceps-based formulations in 240 COPD patients found that one preparation significantly prolonged the time to first acute exacerbation and reduced the frequency of exacerbations over a 24-week treatment period.[2] These findings suggest that Cordyceps supplementation may offer meaningful adjunctive benefit for some individuals with stable COPD, though larger independent replication studies are needed.
Lung Function and Airway Inflammation
Beyond COPD, research has begun to explore Cordyceps in the context of airway hyperreactivity. In a murine asthma model, cordycepin was shown to attenuate airway hyperresponsiveness, reduce mucus hypersecretion, and lower levels of pro-inflammatory cytokines including IL-4, IL-5, and IL-13. The proposed mechanism involved suppression of the p38-MAPK and NF-kB signaling pathways.[3] While animal models do not directly translate to human outcomes, this mechanistic data provides a plausible biological basis for Cordyceps’ traditional use in supporting respiratory function.
The Gut-Lung Axis: An Emerging Mechanism
One of the more intriguing areas of Cordyceps respiratory research involves the gut-lung axis, a bidirectional communication pathway between intestinal microbiota and pulmonary immune function. Research on Cordyceps militaris in a COPD mouse model found that supplementation improved lung function and reduced pulmonary inflammation, in part by ameliorating gut microbiota dysbiosis and increasing short-chain fatty acid (SCFA) production, including acetate, propionate, and butyrate.[4]
This research adds a new dimension to our understanding of how Cordyceps may support respiratory health — not solely through direct airway effects, but also by influencing systemic immune tone via the gut. Metabolomics analysis in the same study identified 11 differential metabolites regulated by Cordyceps, primarily associated with amino acid metabolism pathways, suggesting multiple overlapping mechanisms.
Cordyceps and Oxygen Utilization
Traditional use of Cordyceps at high altitude has long been associated with improved stamina and reduced breathlessness. Some researchers have proposed that adenosine-like compounds in Cordyceps may influence cellular oxygen metabolism, potentially relevant to both athletic performance and respiratory capacity. However, well-controlled human clinical trials specifically examining VO2 max or oxygen utilization in respiratory patients remain limited, and current evidence does not support strong conclusions in this area.
Studies suggesting improved exercise tolerance in COPD patients (as measured by the six-minute walk test) are consistent with broader improvements in respiratory function rather than a direct effect on oxygen extraction at the cellular level. This distinction is important when interpreting supplement marketing claims.
Key Compounds and Their Proposed Roles
Cordycepin
Cordycepin (3′-deoxyadenosine) is the most studied compound in Cordyceps militaris. Research suggests it may modulate inflammatory signaling pathways relevant to airway inflammation, including NF-kB and MAPK cascades. It is also being studied for anti-fibrotic properties, which may have relevance in conditions involving pulmonary fibrosis, though human data in this area remain preliminary.
Polysaccharides
Cordyceps polysaccharides are thought to contribute to immune-modulatory effects. In the context of respiratory health, these compounds may help regulate Th1/Th2 immune balance, potentially relevant to allergic airway conditions. Their prebiotic properties also appear to support gut microbiota composition, which may indirectly influence pulmonary immune responses via the gut-lung axis.
Adenosine
Natural adenosine content in Cordyceps may support bronchial smooth muscle relaxation through adenosine receptor pathways, though this mechanism has primarily been characterized in preclinical settings. The relevance and magnitude of this effect in humans through dietary supplementation has not been definitively established.
Quality and Form Considerations
Most of the clinical research on Cordyceps and respiratory health has used standardized preparations derived from cultured mycelium or whole fruiting bodies, not raw powder products with unverified active compound content. When evaluating supplements, it is worth looking for products that disclose cordycepin content or beta-glucan percentages, and whether extract ratios have been validated. For a broader overview of what to look for on supplement labels, see our guide to Cordyceps and Immune Function.
The form of Cordyceps also matters: C. militaris is the only species that can be reliably cultivated to produce meaningful cordycepin concentrations, while products labeled as C. sinensis mycelium grown on grain substrates may have substantially different bioactive profiles than wild-harvested or certified cultured material.
What the Evidence Does and Does Not Show
The body of research on Cordyceps and respiratory health is growing but remains unevenly distributed. The strongest clinical evidence comes from COPD studies using standardized Cordyceps preparations as adjuncts to conventional treatment, where improvements in lung function metrics and exacerbation frequency have been observed across multiple trials. Evidence for Cordyceps in asthma, pulmonary fibrosis, or general respiratory wellness in healthy individuals remains largely preclinical.
Importantly, no research supports using Cordyceps as a replacement for prescribed respiratory medications. The clinical trials showing benefit used Cordyceps as an addition to, not a substitute for, standard care. Individuals with respiratory conditions should discuss any supplementation with their healthcare provider, particularly given potential interactions with immunosuppressants or blood-thinning agents.
Summary
Research suggests that Cordyceps mushrooms, particularly standardized preparations of Cordyceps sinensis and Cordyceps militaris, may support respiratory function in individuals with COPD as an adjunct to standard treatment. Proposed mechanisms include direct anti-inflammatory effects on airway tissue, modulation of immune signaling pathways via cordycepin, and indirect pulmonary immune support through the gut-lung axis. Preclinical data on airway hyperreactivity adds further mechanistic context. Larger, independently replicated human trials are needed before firm conclusions can be drawn, particularly in conditions beyond COPD.
References
- [1] Ma G, Jin Y. Therapeutic efficacy and pharmacological mechanism of Bailing capsule on chronic obstructive pulmonary disease: a meta-analysis and network pharmacology. Pharm Biol. 2024;62(1):803-817. PMID: 39460586
- [2] Li S, et al. The Effectiveness of Yong Chong Cao Capsule in Patients With Mild to Severe COPD: A Multi-Center, Randomized, Active-Controlled Trial. J Evid Based Med. 2025;18(4):e70091. PMID: 41295088
- [3] Yang X, et al. Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process. Int Immunopharmacol. 2015;26(2):401-8. PMID: 25912153
- [4] Zhang W, et al. Cordyceps militaris alleviates COPD by regulating amino acid metabolism, gut microbiota and short chain fatty acids. J Ethnopharmacol. 2025;346:119701. PMID: 40147677
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Cordyceps supplements are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before starting any new supplement, particularly if you have a respiratory condition or take prescription medications.
